{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT01733082",
            "orgStudyIdInfo": {
                "id": "ML22679"
            },
            "organization": {
                "fullName": "Genentech, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "The Mycophenolate Pregnancy Registry",
            "officialTitle": "The Mycophenolate Pregnancy Registry",
            "therapeuticArea": [
                "Cardiovascular"
            ],
            "study": "the-mycophenolate-pregnancy-registry"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2012-11-30",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-05-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-05-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2012-11-20",
            "studyFirstSubmitQcDate": "2012-11-23",
            "studyFirstPostDateStruct": {
                "date": "2012-11-26",
                "type": "ESTIMATED"
            },
            "lastUpdateSubmitDate": "2024-07-04",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-08",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Genentech, Inc.",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Accord Healthcare, Inc.",
                    "class": "INDUSTRY"
                },
                {
                    "name": "Sandoz",
                    "class": "INDUSTRY"
                },
                {
                    "name": "Apotex Corporation",
                    "class": "UNKNOWN"
                },
                {
                    "name": "Novartis Pharmaceuticals",
                    "class": "INDUSTRY"
                },
                {
                    "name": "Pfizer",
                    "class": "INDUSTRY"
                },
                {
                    "name": "Mylan Pharmaceuticals Inc",
                    "class": "INDUSTRY"
                },
                {
                    "name": "Teva Pharmaceuticals USA",
                    "class": "INDUSTRY"
                },
                {
                    "name": "Alkem Laboratories Ltd",
                    "class": "INDUSTRY"
                },
                {
                    "name": "Roxane Laboratories",
                    "class": "INDUSTRY"
                },
                {
                    "name": "Vintage Pharmaceuticals, LLC",
                    "class": "UNKNOWN"
                }
            ]
        },
        "descriptionModule": {
            "briefSummary": "The Mycophenolate Pregnancy Registry is designed as a prospective, observational registry collecting data regarding mycophenolate exposure during pregnancy, and pregnancy outcomes, fetal and infant outcomes after exposure. Early and later term pregnancy outcomes will be solicited at selected gestational time points. Structural and functional birth defects identified in the perinatal period through one year of life will be collected and classified.\n\nThis is a non-proprietary registry and is a component of a comprehensive pregnancy Risk Evaluation and Mitigation Strategy (REMS) plan required by the FDA for all mycophenolate-formulations, including CellCept, Myfortic and any generic formulations."
        },
        "conditionsModule": {
            "conditions": [
                "Heart Transplantation, Kidney Transplantation, Liver Transplantation, Autoimmune Diseases"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "PROSPECTIVE"
            },
            "enrollmentInfo": {
                "count": 500,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cohort"
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Maternal Outcomes: Incidence of Pregnancy Complications",
                    "timeFrame": "Approximately 13 years"
                },
                {
                    "measure": "Fetal Outcomes: Incidence of Congenital Disorders",
                    "timeFrame": "Approximately 13 years"
                },
                {
                    "measure": "Time/Duration of Mycophenolate Exposure",
                    "timeFrame": "Approximately 13 years"
                },
                {
                    "measure": "Mycophenolate Dose/Regimen",
                    "timeFrame": "Approximately 13 years"
                },
                {
                    "measure": "Indications for Mycophenolate use",
                    "timeFrame": "Approximately 13 years"
                },
                {
                    "measure": "Maternal Medical/Demographic Characteristics",
                    "timeFrame": "Approximately 13 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Occurrence of Educational Counseling on the Increased Risks of Birth Defects With Mycophenolate Therapy",
                    "timeFrame": "Approximately 13 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Pregnancy and reported maternal exposure to mycophenolate during pregnancy or within 6 weeks of discontinuing treatment\n\nExclusion Criteria:\n\n* Pregnancies for which there is paternal exposure only\n* Pregnancies occurring outside the U.S.",
            "healthyVolunteers": false,
            "sex": "FEMALE",
            "stdAges": [
                "CHILD",
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Pregnancy and reported exposure to mycophenolate during pregnancy or within 6 weeks of discontinuing treatment",
            "samplingMethod": "PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Reference Study ID Number: ML22679 https://forpatients.roche.com/",
                    "role": "CONTACT",
                    "phone": "888-662-6728 (U.S. and Canada)",
                    "email": "global.rochegenentechtrials@roche.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Clinical Trials",
                    "affiliation": "Genentech, Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Quintiles Outcome",
                    "status": "RECRUITING",
                    "city": "Cambridge",
                    "state": "Massachusetts",
                    "zip": "02139",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.3751,
                        "lon": -71.10561
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001327",
                    "term": "Autoimmune Diseases"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4629",
                    "name": "Autoimmune Diseases",
                    "asFound": "Autoimmune Diseases",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M12128",
                    "name": "Mycophenolic Acid",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}